Low-dose sodium oxybate for idiopathic hypersomnia sleepiness
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether low-dose sodium oxybate can improve symptoms in adults with idiopathic hypersomnia, a condition that causes excessive sleepiness. You’d likely be asked to pause this standard treatment briefly while baseline testing is completed, and you’d use reliable contraception during and after the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old and have a primary diagnosis of idiopathic hypersomnia (IH) that fits the study’s sleep-disorder criteria
- Your body mass index (BMI) is between 18 and 35
- Most days you sleep at least 9 hours (including naps), based on at least 10 of 14 days of a sleep diary
- You score at least 10 on the Epworth Sleepiness Scale (done at pre-screening)
- A sleep specialist has recommended low-dose sodium oxybate (LSO) as part of usual care, and you agree to delay it until baseline tests are finished
- If you take wake-promoting medicines or antidepressants, your dose must be stable for at least 2 months before starting and stay stable during the main study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how narcolepsy or idiopathic hypersomnia affects thinking and cardiovascular health, and how usual treatment medications may change those outcomes. It may help researchers understand risks and benefits of common hypersomnia therapies.
This study tests whether low sodium oxybate, a medication that improves alertness, can help reduce symptoms like dizziness and fatigue in people who have both idiopathic hypersomnia and POTS. You would stay on your current daytime medications, but some heart-related drugs may be paused temporarily before tests.
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
This study tests a new medication called solriamfetol to see if it safely reduces excessive daytime sleepiness in people with idiopathic hypersomnia. You may receive the study drug or a placebo, and your sleepiness levels will be monitored to see if the treatment helps.
This study tests an investigational medication called TAK-360 for people with idiopathic hypersomnia (IH), a sleep disorder that causes excessive daytime sleepiness. The goal is to see if the drug can help reduce sleepiness and improve daily function.
This trial tests whether taking melatonin at night and using a bright light therapy device in the morning can improve excessive daytime sleepiness in people with idiopathic hypersomnia. It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real treatment or a placebo.
Hear when a new Idiopathic Hypersomnia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.